D. Boral Capital Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 257.14% from the company’s previous close.

Several other equities analysts also recently commented on ANIX. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Trading Down 1.8%

Anixa Biosciences stock traded down $0.05 during mid-day trading on Tuesday, hitting $2.80. The stock had a trading volume of 257,605 shares, compared to its average volume of 158,646. The firm’s 50 day moving average is $2.78 and its 200 day moving average is $2.94. The firm has a market capitalization of $95.26 million, a P/E ratio of -9.03 and a beta of 0.59. Anixa Biosciences has a one year low of $2.32 and a one year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities research analysts forecast that Anixa Biosciences will post -0.31 earnings per share for the current year.

Insider Activity

In related news, CEO Amit Kumar bought 21,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the acquisition, the chief executive officer owned 630,812 shares in the company, valued at $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 26.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANIX. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences during the second quarter valued at approximately $33,000. Cetera Investment Advisers purchased a new stake in shares of Anixa Biosciences in the fourth quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after acquiring an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences during the 2nd quarter worth approximately $37,000. Finally, Millennium Management LLC purchased a new position in Anixa Biosciences during the 4th quarter valued at $38,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.